Kohei Nakamura

Keio University

Papers

1

Total Citations

2

H-Index

1

About

Kohei Nakamura is a clinical researcher whose work centers on the molecular genetics of urologic malignancies, with a particular focus on prostate cancer. His major contribution lies in elucidating the clinical significance of concurrent tumor suppressor gene losses—specifically BRCA2 and RB1—in organ-confined prostate cancer. In his landmark 2021 case study, Nakamura documented the first Japanese instance of this dual-gene co-loss, demonstrating that even localized disease can harbor high-risk genomic features typically associated with aggressive, metastatic tumors. This finding challenges existing risk stratification models and underscores the importance of germline and somatic testing in early-stage prostate cancer. Though his most-cited paper has garnered 2 citations to date, its novelty as a pioneering report in an East Asian population positions it as a foundational reference for future studies on homologous recombination deficiency in Japanese men. Nakamura’s work bridges a critical gap in Asian-specific oncogenomic data, offering actionable insights for personalized surgical and adjuvant therapy decisions. His meticulous case analysis sets a precedent for integrating comprehensive genomic profiling into routine urologic oncology practice.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy
2 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Keio University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago